Overview
Top Medical Research Studies
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Most Useful Reviews
Medical Researches
- All Researches
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
Cardiovascular disease (CVD) is a broad term that encompasses a range of heart and blood vessel disorders. This can include conditions such as coronary artery disease, which leads to heart attacks; cerebrovascular disease that results in strokes; and peripheral artery disease affecting blood flow to the limbs. The key risk factors for CVD often include high blood pressure, high cholesterol, obesity, smoking, a sedentary lifestyle, and diabetes. By identifying and managing these risk factors, individuals can significantly reduce their likelihood of developing cardiovascular problems.
Prevention and treatment strategies often involve lifestyle modifications such as adopting a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, alongside engaging in regular physical activity. In some cases, medications might be necessary to control blood pressure or cholesterol levels. Regular check-ups with a healthcare provider are essential for monitoring heart health, especially for individuals with a family history of CVD. Understanding the signs and symptoms of cardiovascular issues—like chest pain, shortness of breath, or fatigue—can help in seeking timely medical attention, ultimately leading to better outcomes.
Omega-3 fish oil is a nutritional supplement derived from the fatty tissues of fish, particularly fatty fish like salmon, mackerel, and sardines. It is rich in omega-3 fatty acids, which are essential fats that the body cannot produce on its own. The most significant types of omega-3s found in fish oil are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which are known for their numerous health benefits. These include reducing inflammation, supporting heart health, and promoting brain function.
Incorporating omega-3 fish oil into your diet can be beneficial if you don’t consume enough fish regularly. Many health experts recommend oily fish as a part of a balanced diet due to their high omega-3 content. For those who find it difficult to include fish in their meals, fish oil supplements can offer a convenient alternative, providing the same essential fatty acids in concentrated form. However, it’s essential to choose high-quality supplements that are third-party tested for purity and potency to avoid contaminants such as heavy metals or other toxins that can impact health.
Omega-3 fish oil has long been touted for its potential cardiovascular benefits, and numerous studies support the notion that it can be helpful in managing overall heart health. Rich in EPA and DHA, the primary active components in fish oil, omega-3 fatty acids are known to reduce triglyceride levels, lower blood pressure, and may even decrease the risk of arrhythmias. Some research suggests that regular consumption of omega-3s can lead to a reduced risk of heart disease and stroke by improving vascular health and reducing inflammation in the body.
However, it's essential to approach this topic with a balanced perspective. While omega-3 supplements can be beneficial, they should not be seen as a standalone solution for cardiovascular disease. Incorporating omega-3s through diet—such as fatty fish like salmon, sardines, and mackerel—is preferable to relying solely on supplements. Moreover, if you're considering adding fish oil supplements to your routine, it's advisable to consult with a healthcare provider to ensure they fit within your complete cardiovascular health strategy, which should also include a nutritious diet, regular exercise, and other heart-healthy lifestyle choices.
Based on user reviews, the time it takes to see results from taking omega-3 supplements for cardiovascular health can vary. Many users report experiencing noticeable improvements in their overall well-being and cardiovascular function relatively quickly. For instance, one user mentioned immediate positive effects, indicating their grandmother felt amazing after starting the supplement last summer ((Read Review)). Additionally, another user noted reduced blood pressure and a lower risk of cardiovascular issues after consistent use, suggesting results within a short time frame ((Read Review)).
Other users shared similar sentiments, discussing improvements in heart health and cholesterol levels within days or weeks of starting the supplement ((Read Review); (Read Review)). Though individual experiences may vary depending on factors like dosage and overall health, many users seem to echo the sentiment that benefits can be apparent relatively swiftly after initiating omega-3 supplementation.
The role of omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in supporting cardiovascular health is backed by a growing body of scientific research. Numerous studies have demonstrated that these fatty acids can positively influence various cardiovascular risk factors. For instance, higher levels of omega-3 fatty acids have been associated with a reduced risk of cardiovascular events and improved lipid profiles, including increased high-density lipoprotein (HDL) cholesterol and lowered triglyceride levels [30]. Additionally, clinical trials have shown that supplementation with EPA can significantly reduce major cardiovascular risks among high-risk patients, regardless of their baseline low-density lipoprotein (LDL) cholesterol levels [19].
Research also highlights specific beneficial effects of omega-3 fatty acids on heart function, inflammation, and arrhythmia management. Long-term high-dose omega-3 supplementation has been linked to improved heart function in patients with heart failure [36], while omega-3 intake may reduce inflammation and lower rates of atrial fibrillation [40][9]. Overall, the evidence suggests that incorporating omega-3 fatty acids into the diet or as supplements provides a viable strategy for enhancing heart health, especially in those with existing cardiovascular conditions.
Users have reported a variety of improvements in their symptoms after taking omega-3 supplements, particularly concerning cardiovascular health. Many individuals mentioned a noticeable reduction in cholesterol levels and blood pressure, often highlighting the supplement's role in decreasing the risk of heart disease and related issues ((Read Review), (Read Review)). For instance, one user shared their grandmother's remarkable health transformation after beginning the supplement, noting that she looks and feels fantastic after a winter season without illness ((Read Review)).
Beyond cardiovascular benefits, users have also reported improvements in skin health and overall energy levels. Many have claimed that omega-3 supplementation has led to clearer, more vibrant skin, while others have experienced boosts in mood and energy ((Read Review), (Read Review)). While these anecdotal experiences are promising and suggest a positive correlation between omega-3 intake and various health improvements, it's important to note that individual results can differ based on a multitude of factors, including dosage and personal health conditions.
Based on user reviews, many individuals have reported positive experiences when combining omega-3 supplements with other health supplements for managing cardiovascular disease. Users often highlight that omega-3s effectively complement their overall supplement routine, enhancing heart health while also providing additional benefits such as improved skin condition and joint support ((Read Review), (Read Review)). For instance, one user noted that integrating omega-3 into their daily regimen feels essential for health and supports various bodily functions beyond just cardiovascular health ((Read Review)).
Additionally, users emphasize that omega-3 supplements can be taken alongside other daily supplements without adverse effects, making them a versatile addition to any health plan ((Read Review), (Read Review)). The compatibility of omega-3 with other supplements indicates a favorable consensus among users regarding its role in promoting cardiovascular wellness alongside a multi-faceted approach to health management. Overall, those who shared their experiences suggest a combination of supplements can be beneficial, particularly when omega-3 is included for its specific cardiovascular advantages and overall well-being.
When it comes to optimizing cardiovascular health through omega-3 fish oil supplementation, research suggests that high doses are most effective. Particularly, a meta-analysis of 14 studies with nearly 9,100 participants indicated that dosages ranging from 2,000 to 4,000 mg of omega-3 fatty acids per day, sustained over at least one year, significantly improved heart function markers such as left ventricular ejection fraction and peak oxygen consumption [36]. It's noteworthy that lower doses and shorter treatment durations were not found to yield similar benefits, making the higher dosage particularly relevant for individuals managing heart failure or looking to enhance overall cardiovascular performance.
Additionally, the research emphasizes the importance of long-term supplementation, as the benefits observed require consistent intake over time. It's crucial for individuals who are considering omega-3 oil for heart health to consult healthcare professionals to tailor the dosage and duration specific to their health status and genetic background, as factors like individual response to lipid profiles and potential interactions with other treatments can influence outcomes [2].
One year after their first heart event, we found that 32% of these patients were eligible for EPA supplementation, particularly those with elevated triglyceride levels. Notably, eligibility was higher among younger individuals, smokers, diabetics, hypertensive patients, and those who were obese.
We also looked into potential ways to enhance this eligibility through additional lipid-lowering therapies, such as statins and ezetimibe. However, despite these adjustments in treatment strategies, we observed only a slight reduction in the percentage of patients who met the criteria for EPA supplementation.
This finding suggests that there's a significant opportunity to reduce cardiovascular risks in those who qualify for EPA, especially among patients with hypertriglyceridemia. It becomes clear that integrating omega-3 fatty acids into treatment plans could be beneficial for many patients in this high-risk group.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
We found that higher levels of DHA were inversely associated with various inflammatory markers, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Additionally, specific DHA-derived compounds appeared to correlate with lower levels of inflammatory markers, suggesting that these lipid mediators could help regulate inflammation.
While our findings are promising, demonstrating a link between DHA and reduced inflammation markers, we did not directly assess the effects on cardiovascular disease outcomes. Therefore, while DHA shows potential benefits in modulating inflammation, its direct impact on cardiovascular health remains to be conclusively determined.
Evidence suggests that these beneficial fatty acids can lower heart disease risk, improve blood pressure, and enhance lipid profiles.
While advancements in fortifying foods with Dω-3 PUFAs show promise, there's still a need for more research to maximize their health benefits and ensure better protection against CVDs.
In this study, 86 adults participated in a 4-week fish oil program, and their lipid profiles were assessed before and after the supplementation.
We found that genetic variations, specifically in the FADS1 and ELOVL2 genes, might affect how well the body utilizes omega-3 fatty acids.
This highlights the potential for personalized nutrition to enhance cardiovascular health.
References
- Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
- Medoro A, Graziano F, Cardinale G, Voccola S, Zotti T, et al. The influence of FADS1 and ELOVL2 genetic polymorphisms on polyunsaturated fatty acid composition in response to fish oil supplementation. Lipids Health Dis. 2025;24:102. doi:10.1186/s12944-025-02513-w
- Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
- Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Mao Q, Tian X, Wang X, Xu H, Zhang Y, et al. Global burden of cardiovascular diseases attributable to diet low in seafood omega-3 fatty acids from 1990~2021 and forecasting the future trends: A population-based study. PLoS One. 2025;20:e0316767. doi:10.1371/journal.pone.0316767
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
- Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
- Dong S, Wang Y, Bian J, Chen H, Dong J, et al. The effect of omega-3 Polyunsaturated Fatty Acid (PUFA) prescription preparations on the prevention of clinical cardiovascular disease: a meta-analysis of RCTs. Nutr J. 2024;23:157. doi:10.1186/s12937-024-01051-y
- Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
- Brosolo G, Da Porto A, Marcante S, Capilupi F, Bertin N, et al. The role for ω-3 polyunsaturated and short chain fatty acids in hypertension: An updated view on the interaction with gut microbiota. Eur J Pharmacol. 2024;985:177107. doi:10.1016/j.ejphar.2024.177107
- Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Li ZH, Song WQ, Qiu CS, Li HM, Tang XL, et al. Fish oil supplementation, genetic susceptibility and risk of new-onset hypertension. Prev Med. 2024;189:108152. doi:10.1016/j.ypmed.2024.108152
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. doi:10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. doi:10.3390/jcdd12020060
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. doi:10.1016/j.prostaglandins.2025.106948
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. doi:10.3390/nu16213614
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. doi:10.1016/j.plefa.2024.102655
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. doi:10.1016/j.athplu.2024.09.002
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. doi:10.3390/ijms251810136
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. doi:10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. doi:10.3390/jcdd12020060
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. doi:10.1007/s11357-025-01544-6
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. doi:10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. doi:10.1039/d4fo04961f
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. doi:10.1016/j.prostaglandins.2025.106948
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. doi:10.3390/nu16233995
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. doi:10.1016/j.plefa.2024.102655
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. doi:10.3390/ijms251810136
